Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease
Samantha Budd Haeberlein(Biogen (United States)), Alfred Sandrock(Biogen (United States)), Cath Mummery(UK Dementia Research Institute), Craig Mallinckrodt(Biogen (United States)), Ivan Nestorov(St. Josef-Hospital), Ying Zhu(Biogen (United States)), Oskar Hansson(Eli Lilly (United States)), Bruno Vellas(Centre Hospitalier Universitaire de Toulouse), Christian von Hehn(Biogen (United States)), LeAnne Skordos(Biogen (United States)), Frederik Barkhof(National Hospital for Neurology and Neurosurgery), Kumar Kandadi Muralidharan(Biogen (United States)), Katie Harrison(Biogen (United States)), Takeshi Iwatsubo(National Center of Neurology and Psychiatry), Christopher H. van Dyck(Yale University), Y. Tian(Biogen (United States)), Tianle Chen(Biogen (United States)), Sifan Wu(Biogen (United States)), Gersham Dent(Biogen (United States)), Paul Aisen(University of Southern California), Raj Rajagovindan(Biogen (United States)), Spyros Chalkias(Moderna Therapeutics (United States)), Laura Nisenbaum(Biogen (United States)), Sarah Cohen
Cited by 1,330
Related Papers
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
|Alzheimer s & Dementia|2018|10.4k
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
|Alzheimer s & Dementia|2011|7.1k
Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration
|The Lancet Neurology|2013|5.4k
Lecanemab in Early Alzheimer’s Disease
|New England Journal of Medicine|2022|5k